In a report released on January 31, Elizabeth Anderson CFA from Evercore ISI maintained a Hold rating on Quest Diagnostics (DGX – Research ...

Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $178 from $177 and keeps an Outperform rating on the shares following the ...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune® magazine, ...

Quest Diagnostics (NYSE:DGX), a leader in diagnostic testing and information services, released its fourth quarter results on ...

Quest Diagnostics reported fourth-quarter revenue of $2.62 billion, beating analyst estimates of $2.58 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of ...

CEO Jim Davis reported a nearly 15% revenue growth for Q4, including 5% organic growth, and close to 7% revenue growth for the full year, supported by eight acquisitions. He highlighted the Advanced ...

Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) reached a new 52-week high during mid-day trading on Thursday after the company announced better than expected quarterly earnings.

This was the stock's second consecutive day of losses.

Securities showed confidence in Quest Diagnostics (NYSE:DGX) by increasing the company's price target to $178 from the ...

Quest Diagnostics is a leading provider of independent ... Finally, Quest's scale and reach make the company an attractive partner for the researchers who invent various diagnostic tests but ...

Quest Diagnostics' fourth-quarter net income and revenue rose beyond Wall Street expectations, and the medical firm forecast more growth in 2025 amid rising demand for its health-care tests.

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine ...